IGF1 and prostate carcinoma: Further research may consider other assays that estimate the bioavailability of circulating IGF-I, as well as methods for measuring free IGF-I in prostate tissue, to deepen the understanding of potential pathways and mechanisms for the substantiated association between circulating total IGF-I and subsequent prostate cancer development and progression.